Skip to main
PSNL

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 0%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Personalis Inc. has demonstrated a positive trajectory with increased volumes expected in Q4, particularly due to the anticipated marketing push by its commercial partner, Tempus. The company achieved a significant milestone by obtaining Medicare coverage and pricing for its NeXT Personal MRD test, which is poised to enhance early detection of cancer recurrence, supporting a strong value proposition in genomic testing. Additionally, the favorable agreements with large pharmaceutical partners, including a $50 million stock purchase from Merck and improved sales estimates for upcoming years, further indicate a strong growth potential for Personalis's products, reinforcing a favorable outlook for the stock.

Bears say

Personalis Inc has experienced a negative shift in its financial outlook due to a reduction in revenue guidance, attributing a significant portion of the anticipated decline to a slowdown in biopharma activities and logistical challenges with global sample processing. The company's revised revenue expectations for 2025 have been decreased to a range of $68 million to $73 million, reflecting a year-over-year decline primarily driven by reduced contributions from biopharma services. Additionally, uncertainties regarding sample flow for MRD testing and delays in reimbursement approvals further complicate the revenue landscape, signaling potential ongoing challenges in achieving profitability amidst these operational hurdles.

Personalis Inc (PSNL) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 0% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Personalis Inc (PSNL) has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.